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Abstract
Background: MicroRNAs (miRNAs) are small regulatory molecules that cause translational repression by base pairing with 
target mRNAs. Cumulative evidence suggests that changes in miRNA expression may in part underlie the pathophysiology 
and treatment of neuropsychiatric disorders, including major depressive disorder (MDD).
Methods: A miRNA expression assay that can simultaneously detect 423 rat miRNAs (miRBase v.17) was used to profile 
the prefrontal cortex (PFC) of a genetic rat model of MDD (the Flinders Sensitive Line [FSL]) and the controls, the Flinders 
Resistant Line (FRL). Gene expression data from the PFC of FSL/FRL animals (GEO accession no. GSE20388) were used to guide 
mRNA target selection. Luciferase reporter assays were used to verify miRNA targets in vitro.
Results: We identified 23 miRNAs that were downregulated in the PFC of the FSL model compared with controls. Interestingly, one 
of the identified miRNAs (miR-101b) is highly conserved between rat and human and was recently found to be downregulated in the 
PFC of depressed suicide subjects. Using a combination of in silico and in vitro analyses, we found that miR-101b targets the neuronal 
glutamate transporter SLC1A1 (also known as EAAC1 or EAAT3). Accordingly, both mRNA and protein levels of SLC1A1 were found to 
be upregulated in the PFC of the FSL model.
Conclusions: Besides providing a list of novel miRNAs associated with depression-like states, this preclinical study replicated the 
human association of miR-101 with depression. In addition, since one of the targets of miR-101b appears to be a glutamate transporter, 
our preclinical data support the hypothesis of a glutamatergic dysregulation being implicated in the etiology of depression.
Keywords: epigenetics, miRNA, depression, EAAC1, DCBXA
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Introduction
MicroRNAs (miRNAs) are a family of small, on average 22 nucle-
otides long, non-coding RNAs that regulate gene expression at 
the posttranscriptional level (Winter et al., 2009). Most known 
mammalian miRNAs are expressed in a tissue-specific man-
ner, cause translational repression, and can individually target 
hundreds of genes (He and Hannon, 2004). A known mechanism, 
through which miRNAs exert their repressive function, involves 
their incorporation into the RNA-induced silencing complex 
(RISC), which uses the miRNA’s seed region (nucleotides 2–8 at 
the 5’ end of the miRNA) as a template for recognizing com-
plementary sites in the 3’ untranslated region (UTR) of target 
mRNAs (Winter et al., 2009). The latter mRNA targeting by miR-
NAs leads to mRNA degradation, destabilization, or translational 
inhibition (Winter et al., 2009).
The human genome codes for thousands of miRNAs (Londin et 
al., 2015), and over 60% of protein-coding genes seem to have been 
under selective pressure to maintain miRNA pairings (Friedman 
et al., 2009). Not unexpectedly, miRNAs have been found to play 
an important role in human diseases, including cancer, cardiovas-
cular disease, and other pathological conditions involving stress 
responsive pathways (Mendell and Olson, 2012). Within the nerv-
ous system, miRNAs are thought to contribute to brain develop-
ment, neural function, and synaptic plasticity (Forero et al., 2010). 
Dysregulation of specific miRNAs has been observed in both 
patients and animal models of neuropsychiatric disorders, includ-
ing addiction, anxiety, autism, and schizophrenia (Forero et al., 
2010; Miller and Wahlestedt, 2010; Moreau et al., 2011; Chan and 
Kocerha, 2012). A critical component necessary for miRNA biogen-
esis, Dicer1, has also been implicated in posttraumatic stress and 
anxiolytic responses (Dias et al., 2014; Wingo et al., 2015).
With regard to major depressive disorder (MDD), the evi-
dence supporting a miRNA involvement in the pathophysiol-
ogy and the treatment of the disorder is increasing (Dwivedi, 
2016). More specifically, genetic polymorphisms in different 
miRNAs (e.g., miR-30e and miR-182) have been associated with 
MDD (Saus et al., 2010; Xu et al., 2010). In addition, certain miR-
NAs (e.g., miR-16, miR-135, miR-335, and miR-1202) have been 
found to contribute to the therapeutic action of antidepres-
sants, including that of selective serotonin re-uptake inhibitors, 
tricyclics, and ketamine (Baudry et al., 2010; Launay et al., 2011; 
O’Connor et al., 2013; Issler et al., 2014; Lopez et al., 2014; Li et al., 
2015). Separate studies also found that the expression levels of 
a number of miRNAs were changed in blood samples (Bocchio-
Chiavetto et al., 2013; Fan et al., 2014) and fibroblasts (Garbett 
et al., 2015) of patients with MDD. Finally, a miRNA expression 
study that profiled the prefrontal cortex (PFC) of antidepressant-
free depressed suicide subjects found 21 downregulated miR-
NAs, including miR-101 (Smalheiser et al., 2012), and one study 
showed increased miR-511 levels in basolateral amygdala from 
depressed subjects (Yang et al., 2014).
In the present study, we used a well-established genetic rat 
model of MDD (the Flinders Sensitive Line [FSL]) and its controls 
(the Flinders Resistant Line [FRL]) to provide further insights 
into a possible miRNA dysregulation in depression-like states. 
FSL rats exhibit some key characteristics of MDD, including 
anhedonia, emotional memory impairment, and psychomo-
tor retardation, all of which are reversed by antidepressant 
treatment (Overstreet et al., 2005; Eriksson et al., 2012). At the 
molecular level, FSL animals have reductions in levels of sero-
tonin receptors (Eriksson et al., 2012) and other key molecules 
associated with MDD, including BDNF, NPY, and P11 (Melas 
et al., 2012a, 2012b, 2013; Wei et al., 2015). The FSL also exhibits 
a dysfunctional regulation of glutamate transmission and has 
a reduction of both neuronal and glial glutamate receptors and 
transporters (Eriksson et  al., 2012; Gomez-Galan et  al., 2013). 
This is of relevance, given the accumulating evidence that sug-
gests an aberrant glutamatergic signaling in humans with MDD 
(Sanacora et al., 2012) in combination with the promising role of 
novel antidepressant compounds that act as glutamate receptor 
modulators (Caddy et al., 2015).
Methods
Animals
Adult, 3-month-old, male FSL and FRL rats (n = 6–7/group) were 
used for this study. The number of animals used for each experi-
ment is denoted in the respective methodological section or 
figure legend. PFC regions and hippocampi of all animals were 
dissected according to Glowinski and Iversen (1966) and immedi-
ately stored at -80°C until subsequent experimental analyses. All 
experiments were approved by the Danish National Committee 
for Ethics in Animal Experimentation and the Ethical Committee 
for protection of animals at the Karolinska Institutet.
RNA Extraction and Reverse Transcription
Total RNA from the PFC and one hippocampus of each FSL/FRL 
animal were extracted using the miRNA Universal Kit (Qiagen) 
followed by treatment with DNase I  (Qiagen) to digest con-
taminating DNA. Concentrations were determined using the 
NanoDrop ND-1000 (NanoDrop Technologies Inc.). For miRNA 
analyses, complementary DNA (cDNA) was synthesized using 
the Universal cDNA Synthesis Kit II for RT-PCR (Exiqon) accord-
ing to the manufacturer’s protocol. UniSp6 RNA was spiked 
in for monitoring conversion efficiency. For mRNA analyses, 
cDNA was synthesized using the SuperScript III First-Strand 
Synthesis System for RT-PCR (Invitrogen; Life Technologies) 
according to the manufacturer’s protocol. cDNA and RNA sam-
ples were stored at -20oC and -80oC, respectively, until further 
processing.
Significance Statement
MicroRNAs (miRNAs) are small non-coding RNA molecules that cause messenger RNA silencing. In the present study, 
we found miRNA changes in an established rodent model of major depressive disorder (MDD). Interestingly, one of the 
dysregulated miRNA (miR-101) was recently also identified as being affected in postmortem brain samples of human 
MDD subjects. To further our understanding on miR-101b’s function, we used in vitro assays and found that it targets 
the neuronal glutamate transporter SLC1A1 (also known as EAAC1 or EAAT3). These preclinical findings suggest a 
glutamatergic dysregulation in MDD and support the literature showing efficacy of novel antidepressant compounds 
that act as glutamate receptor modulators.
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miRNA Profiling
The nCounter Rat miRNA Expression Assay (NanoString 
Technologies, Inc.), which includes 423 rat miRNAs derived from 
miRBase (version 17), was used to profile miRNA expression in 
the PFC of FSL/FRL animals. In brief, 100 ng of total RNA in 5 µL 
(n = 6 FSL, n = 6 FRL) was used for hybridizations of each miRNA 
assay according to the manufacturer’s instructions. The miRNA 
raw data were normalized for lane-to-lane variation using a 
dilution series of 6 spike-in positive controls. The normalization 
factor for each lane was calculated as follows: the sum of the 6 
positive controls for a given lane, divided by the average sum 
across lanes. The normalization factor was then multiplied by 
the raw counts of each lane to produce a normalized value. The 
background level of each lane was defined as 2 SD above the sig-
nal of the no-target sequence (negative) controls. We included a 
miRNA probe in the subsequent analyses only if at least 5 of 6 
samples, of either FSL or FRL, had levels above the background 
value.
Gene Expression Microarray Data and Pathway Analysis
In a previous study, Blaveri et  al. (2010) used 2 independent 
cohorts of male FSL and FRL animals to conduct a genome-
wide mRNA expression profiling of the hippocampus and PFC. 
For the purposes of their study, they used the Affymetrix Rat 
Genome 230 2.0 GeneChips and deposited the microarray data 
in the GEO microarray database (accession no. GSE20388). To 
guide our selection of putative miRNA targets, we retrieved the 
microarray PFC data sets and reprocessed them using a mixed 
model ANOVA according to the initial publication (Blaveri et al., 
2010). Since we found a main downregulation of miRNAs in the 
PFC of FSL animals, we further filtered the microarray probe-
set to include only the mRNAs that showed upregulation in the 
FSL in both analyzed cohorts with a combined P value of < .05. 
The filtered probe-sets were then imported into the Ingenuity 
Pathway Analysis (IPA; Qiagen) for miRNA target predictions and 
also for analyzing pathways, diseases, and biofunctions, includ-
ing molecular and cellular functions and physiological system 
development and functions.
Coexpression Analysis
A miRNA coexpression analysis was performed based on the 
method in Smalheiser et al. (2011) with a minor modification. 
MiRNA pairs were filtered based on 3 criteria: (1) they showed 
significant pairwise expression level correlations (r > 0.8) across 
the individual rats in the FSL group; (2) the corresponding pair-
wise correlations in the FRL group were significantly less than 
those in the FSL group (rFSL - rFRL > 0.8); and (3) the miRNA 
pairs were not significantly negatively correlated in the FRL 
group (rFRL > -0.8).
Validation of miRNAs and mRNA Expression Levels
Validation experiments of miRNA hits and measurements of puta-
tive mRNA targets, in the PFC of FSL/FRL animals, were performed 
using quantitative real-time PCR (qRT-PCR). All qRT-PCR amplifi-
cations, as well as that in hippocampal cDNA, were performed in 
triplicates using Power SYBR Green (Applied Biosystems) on an ABI 
PRISM 7900 HT Sequence Detection System (Applied Biosystems), 
with the following conditions: 95°C for 10 minutes, followed by 40 
repeats of 95°C for 15 seconds (10 seconds for miRNA amplifica-
tion), 60°C for 1 minute, and a final dissociation stage to monitor 
amplification specificity. For miRNA expression analyses, LNA PCR 
primers (Exiqon) were used to amplify miRNAs of interest, and the 
data were normalized to Rnu5g. For mRNA expression analyses, 
conventional primers were used and data were normalized to 2 
reference genes (Mff, mitochondrial fission factor; and Cdipt, CDP-
diacylglycerol--inositol 3-phosphatidyltransferase). Relative gene 
expression quantifications were calculated using the qBase software 
(version 1.3.4) (Hellemans et al., 2007). The tested genes and corre-
sponding primer pair sequences are listed in supplementary Table 
1.
Protein Expression Levels
Protein expression levels of SLC1A1 (also known as EAAC1, 
EAAT3, or DCBXA), in the PFC of FSL/FRL animals, were quanti-
fied using Western blotting as previously described (Wei et al., 
2015). Primary antibody incubations were performed overnight 
at 4°C with a mouse monoclonal anti-EAAT3 antibody (1:1000 
dilution, ab78395; Abcam) and with a mouse monoclonal anti-
β-actin antibody (1:10,000 dilution, A5316; Sigma-Aldrich) as 
loading control. Membranes were exposed to the Amersham 
ECL Plus Western Blotting Detection reagent (GE Healthcare), 
and immunoreactive bands were detected using the Amersham 
Hyperfilm ECL (GE Healthcare). Optical densities were quantified 
using the NIH ImageJ software (1.47 version). SLC1A1 protein 
expression levels were normalized to the expression levels of 
β-actin and the data were presented as relative quantifications.
In Vitro Verification of miRNA Targets
To examine whether SLC1A1 is a direct target of miR-101b, 
we used LightSwitch 3’UTR luciferase reporter constructs 
(SwitchGear Genomics). HEK 293 cells were co-transfected with 
100 ng of a human SLC1A1 GoClone 3’UTR reporter (S810654, 
SwitchGear Genomics) and either 50 nM of a miR-101b mimic or 
50 nM of a miRNA non-targeting control (Switchgear Genomics) 
using DharmaFECT Duo transfection reagent (GE Dharmacon). 
An empty vector (no 3’UTR; SwitchGear Genomics) was used as 
a control. Luciferase activity was measured on a plate luminom-
eter 24 hours after transfection by adding 100 µL of LightSwitch 
Assay Reagent (SwitcGear Genomics). In total, the experiment 
was replicated 3 times with at least 3 biological replicates each 
time.
Statistical Analyses
Data in the bar graphs are presented as mean values ± 1 SEM. 
The normal distribution of the data and the homogeneity of 
variances were tested using the Shapiro-Wilk and Levene’s 
tests, respectively. The miRNA expression levels of FSL vs FRL, 
generated by the NanoString nCounter Rat miRNA assay, were 
compared using the Mann-Whitney U-test. The difference of 
miRNA expression levels, generated by RT-PCR, between FSL 
and FRL was assessed using the 2-tailed Student’s t test if the 
variances in FRL and FSL were equal or was otherwise assessed 
using the Mann-Whitney U test. The difference in miRNA 
expression variation between FSL vs. FRL was assessed by com-
paring the coefficients of variance of individual miRNAs using 
Mann-Whitney U-test. The threshold for statistical signifi-
cance was set at P < .05. All analyses were performed using IBM 
SPSS Statistics version 22 (IBM Corporation). Extreme values 
are defined as potential outliers using box-plot function from 
SPSS software that are denoted in the figure legends and were 
excluded from the analyses.
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Results
Downregulation of miRNAs in the PFC of the FSL 
Animals
To detect putative changes in miRNA expression in the PFC of 
FSL (vs control FRL) animals, we used a miRNA expression assay 
that enables multiplex detection of >400 rat miRNAs. After data 
normalization, only 121 miRNAs were above the background 
level in both rat strains, in agreement with the fact that most 
miRNAs are expressed in a tissue-specific manner (He and 
Hannon, 2004). We found a global miRNA expression decrease in 
the FSL animals that is characterized by depression-like behav-
ior (supplementary Table 2). By plotting the relationship between 
the standard deviations and the mean expression values across 
all expressed miRNAs, we also observed that the miRNA expres-
sion in the FSL rats was significantly more variable compared 
with control FRL (P < .001) (Figure  1). Using individual tests of 
statistical significance, we identified 23 miRNAs with lower (at 
least 30%) expression levels in the FSL rats (P < .05, Benjamini-
Hochberg False Discovery Rate < 0.22; for the full list of miR-
NAs, see supplementary Table 2). To validate these observations, 
we selected 9 miRNAs that showed differential expression and 
performed individual qRT-PCR experiments. The latter analyses 
confirmed that all selected miRNAs had decreased expression 
levels in the FSL, with 8 of the 9 miRNAs reaching statistical sig-
nificance (Figure 2). We also performed a coexpression analysis 
and found that in total, 244 miRNA pairs had correlated expres-
sion levels only in the FSL group. Of those, 51 miRNAs were sig-
nificantly coexpressed with at least 3 other miRNAs in this set 
(supplementary Table 3), including 7 of the 23 miRNAs that were 
significantly decreased in the FSL. Several of these 51 miRNAs 
belong to the let-7 miRNA family (let-7a, 7b, 7c, 7d, 7f, and 7i). 
Some miRNAs (miR-125a-3p and miR-125a-5p, miR-125b-3p and 
miR-125b-5p, rno-miR-3563-3p and miR-3563-5p) derive from 
the same precursor miRNA.
Pathway Analyses and miRNA Target Predictions
Since miRNAs have been shown to correlate negatively 
with levels of target mRNAs (Winter et al., 2009), the miRNA 
downregulation observed in the FSL model may lead to an 
upregulation of their mRNA targets. Among the 23 differen-
tially expressed miRNAs, 16 had information about targets in 
IPA. In a previous study, Blaveri et al. (2010) used PFC regions of 
the FSL/FRL model to conduct a genome-wide mRNA profiling 
study. After retrieving the latter microarray dataset, we reana-
lyzed the data by focusing on the probe sets that showed a sig-
nificant upregulation (P < .05) in the FSL. Next, we tested for an 
overlap between the latter mRNA candidates and the targets of 
the 16 differentially expressed miRNAs using IPA. The analysis 
revealed 1392 potential mRNA targets that were either predicted 
in silico or had been experimentally observed (supplementary 
Table 4). The core analysis in IPA suggested that the target genes 
are involved in canonical pathways involved in protein ubiq-
uitination, Ephrin receptor signaling, and Dopamine-DARPP32 
signaling (Table 1). These genes were also associated with neu-
rological diseases, psychiatric and psychological disorders, and 
monogenic disorders (Table 1).
Gene Expression Measurements of miR-101b Targets
The human homolog of one of the miRNAs that was confirmed 
to be downregulated in the FSL, miR-101b, was found to be down-
regulated in the PFC of depressed suicide subjects (Smalheiser 
et  al., 2012). Therefore, miR-101b was considered to warrant 
further examination. First, we tested if miR-101b showed differ-
ent expression levels in the hippocampus, another brain region 
implicated in MDD, of the FSL/FRL model. We found that hip-
pocampal miR-101b expression levels were not different between 
FSL and FRL (P = .86) (supplemental Figure  1). Further, there is 
high conservation between the mature rat miR-101b and the 
mature human miR-101, which share the same seed sequence 
(Figure  3). A  total of 248 genes were predicted to be miR-101b 
targets (supplementary Table  5), among which 103 genes were 
also part of the IPA pathway genes. From this list, we identified 8 
genes that showed high conservation between human and rat in 
their 3’UTR and were also implicated in depression-related path-
ways in IPA (including glutamate, GR or GABA receptor signaling, 
and NFR2-mediated oxidative stress response). The mRNA levels 
of these 8 genes (Slc1a1, Gabrb2, Adcy5, Gclc, Pbrm1, Prkaa1, Rac1, 
and Smardca4) were therefore measured in the PFC of the FSL/FRL 
animals. We found that 2 genes, Slc1a1 and Rac1, showed signifi-
cantly increased mRNA levels in the FSL (Figure 4a), in line with 
the decreased levels of miR-101b.
MiR-101b Targets SLC1A1 in Vitro and Correlates 
Negatively with SLC1A1 Protein Levels in Vivo
Next, we chose to focus on SLC1A1 (also known as EAAC1 or 
EAAT3), since it is a neuronal glutamate transporter that is 
highly enriched in the cortex (Rothstein et al., 1994). In addition, 
the FSL model is known to exhibit a dysfunctional regulation of 
glutamate transmission (Gomez-Galan et al., 2013). It was there-
fore of interest to verify that the elevated mRNA levels of Slc1a1 
in the FSL rats were due to a specific miR-101b targeting of the 
Slc1a1 3’UTR. For this purpose, HEK 293 cells were transfected 
with a luciferase reporter construct containing the human 
SLC1A1 3’UTR, which contains the same sequence used for 
miRNA seed complementarity as the rat Slc1a1 3’UTR (Figure 3). 
There was a significant reduction in luciferase activity when the 
SLC1A1-3’UTR luciferase construct was cotransfected with the 
miR-101b mimic compared with the SLC1A1-3’UTR luciferase 
construct alone (P = .004) (Figure 4b) or when the SLC1A1-3’UTR 
luciferase construct was cotransfected with a nontargeting 
Figure 1. Plot of log10Mean vs log10Standard deviation based on the microRNA 
(miRNA) assay expression levels in the prefrontal cortex (PFC) of the Flinders 
Sensitive Line (FSL) vs control-Flinders Resistant Line (FRL) animals. MiRNA 
expression in the FSL depression model showed significantly more variation 
compared with controls. Polynomial (order = 2) fitting line was added to each 
rat strain, with the FSL represented by the solid line and the control-FRL by the 
dashed line.
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control (P = .034) (Figure  4b). The latter results supported the 
notion of miR-101b directly targeting Slc1a1, in line with the 
miR-101b downregulation and the elevated Slc1a1 mRNA levels 
observed in the PFC of the FSL. Finally, since mRNA levels do 
not always correlate with protein levels (Vogel and Marcotte, 
2012), we verified that SLC1A1 protein levels were also upregu-
lated in the PFC of the FSL rats compared with the FRL (P = .004) 
(Figure 4c).
Discussion
There is evidence supporting the miRNA involvement in the 
pathophysiology and the treatment of MDD (Dwivedi, 2016). In 
this study, we used the FSL rat model of depression to provide 
further insights into a possible miRNA dysregulation in depres-
sion-like states. By using a miRNA expression-profiling assay, 
which covers >400 known miRNAs, we first observed that the 
overall miRNA expression in the PFC of the FSL model was down-
regulated. This finding coincides with a recent human study that 
showed a 17% global downregulation of miRNAs in the PFC of 
depressed suicide subjects (Smalheiser et al., 2012). However, in 
another rat model of depression, both up- and downregulation 
of miRNA expression was observed, suggesting an exposure pro-
tocol and strain-specific miRNA expression difference (Dwivedi 
et al., 2015). In contrast, an increase in global miRNA expression 
was observed in postmortem cortical regions of subjects with 
schizophrenia, which was found to correlate with an increase in 
the RNase III Drosha that is involved in the processing of miR-
NAs (Beveridge et al., 2010). Drosha has been shown to account 
for widespread downregulation of miRNAs in cancer (Thomson 
et al., 2006), and our data (Wei et al., 2016) show that the global 
downregulation of miRNAs observed in the FSL model is also 
associated with a basal reduction in Drosha levels.
Using individual tests of statistical significance, we identified 
23 specific miRNAs that were decreased in the PFC of the FSL 
model compared with controls. In general, miRNAs are known 
to exert a translational repressive function that involves their 
Table 1. Core Analysis Result from IPA
Top Pathways, Diseases, and Biofunction
P-Value/P-Value 
Range
Top Canonical Pathways
Protein ubiquitination pathway 4.48E-13
Ephrin receptor signaling 8.56E-07
Dopamine-DARPP32 feedback in cAMP 
signaling
1.64E-06
Ephrin B signaling 3.26E-06
Axonal guidance signaling 3.42E-06
Top Diseases
Neurological disease 3.19E-03 - 1.41E-16
Psychological disorders 2.72E-03 - 1.41E-16
Skeletal and muscular disorders 2.72E-03 - 1.99E-16
Hereditary disorder 2.97E-03 - 5.43E-16
Molecular and Cellular Functions
Cellular assembly and organization 3.26E-03 - 6.36E-24
Cellular function and maintenance 3.26E-03 - 6.36E-24
Molecular transport 2.72E-03 - 8.20E-18
Protein trafficking 5.89E-05 - 1.11E-16
Posttranslational modification 3.31E-03 - 7.54E-16
Physiological System Development and Function
Organismal survival 9.34E-04 - 2.52E-14
Nervous system development and function 3.22E-03 - 1.78E-13
Tissue development 3.28E-03 - 1.78E-13
Behavior 3.28E-03 - 4.57E-08
Top Networks
Embryonic development, organismal 
survival, cell death and survival
neurological disease, psychological 
disorders, organismal injury and 
abnormalities
free radical scavenging, small molecule 
biochemistry, hereditary disorder
cellular assembly and organization, cellular 
movement, nervous system development 
and function
Abbreviation: IPA, Ingenuity Pathway Analysis.
Figure 2. The microRNA (miRNA) assay identified 23 miRNAs with lower expression levels in the prefrontal cortex (PFC) of the Flinders Sensitive Line (FSL) depression model 
(supplementary Table 2), and we selected 9 of them for individual validation experiments. Eight of the 9 miRNAs reached statistical significance (miR-10a, P = .046; miR-101b, 
P = .011; miR-107, P = .02; miR-124, P = .03; miR-125a, P = .048; miR-125b, P = .2; miR-133a, P = .03; miR-181a, P = .032, and miR-199a, P = .029). Data are presented as relative 
quantifications (R.Q.) ± SEM. Levels of Rnu5g were used as reference for normalization of mature miRNA expression levels (n = 6–7 animals/group; n = 1 outlier/group),*P < .05.
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Figure 4. (a) From a list of >200 genes that were predicted to be miR-101b targets (supplementary Table 5), we identified 8 genes that showed high conservation between 
human and rat in their 3’ untranslated region (UTR) and were also implicated in depression-related pathways. The mRNA expression of these 8 genes was quantified 
in the prefrontal cortex (PFC) of the Flinders Sensitive Line (FSL) and control-Flinders Resistant Line (FRL) animals. Only Slc1a1 and Rac1 mRNA levels were significantly 
increased in the FSL compared with controls (Slc1a1: P = .001; Rac1: P = .023; P-values of the other 6 genes >.2). (b) Luciferase activity was measured in HEK293 cells 
transfected with either an empty vector (first bar; positive control), an SLC1A1-3’UTR luciferase construct (second bar), an SLC1A1-3’UTR luciferase construct cotrans-
fected with a nontargeting control (third bar; negative control), or an SLC1A1-3’UTR luciferase construct cotransfected with a miR-101b mimic (fourth bar). MiR-101b 
significantly inhibited the luciferase activity of the reporter construct containing the 3’UTR (fourth bar) compared with both SLC1A1 alone (second bar) and SLC1A1-
3’UTR cotransfected with a nontargeting control (third bar). (c) In line with the increased levels of Slc1a1 mRNA, the FSL also showed increased protein levels of SLC1A1. 
Representative immunoblotting images of SLC1A1 and β-actin (loading control) are shown below the graph. Data are presented as relative quantifications (R.Q.) ± SEM. 
Two reference genes (Cdipt and Mff) were used for normalization in 4a (n = 5–7 animals/group). *P < .05, **P < .01.
Figure 3. The sequences of the mature miR-101 and the 3’ untranslated region (UTR) of the SLC1A1 gene in human, rat, and mouse is shown. The mature miR-101 
sequence is highly conserved between species, with only one nucleotide difference between human and rat/mouse (the nucleotide difference is underlined in the 
human sequence). The target site in the 3′-UTR of the SLC1A1 gene was predicted by TargetScan and shows that both the miR-101 seed region (5’-UACAGUAC-3’) and 
the mRNA target site are conserved between human and rat/mouse.
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incorporation into the RISC, which uses the miRNA’s seed region 
as a template for recognizing complementary sites in the 3’ UTR 
of target mRNAs (Winter et al., 2009). When we tested for pre-
dicted mRNA targets of the significant miRNAs and analyzed the 
data using pathway analysis software, we found that the puta-
tive target genes are involved in protein ubiquitination, Ephrin 
receptor signaling, and Dopamine-DARPP32 signaling. Protein 
ubiquitination is known to play an important role in neuronal 
function (Tai and Schuman, 2008), Ephrin ligands and their 
receptors regulate synapse formation and neuronal plasticity 
(Klein, 2009), and Dopamine-DARPP32 is extensively involved 
in intracellular signaling pathways and integrating dopaminer-
gic and glutamatergic signaling (Girault and Greengard, 2004). 
Accordingly, the same genes were associated with both neuro-
logical and psychiatric disorders, for example MDD, in the path-
way analysis. However, besides the overall analysis of the miRNA 
list, one specific miRNA (miR-101) was of particular interest, 
since it was found to be downregulated in the PFC of depressed 
suicide subjects (Smalheiser et al., 2012). Using a combination 
of in silico and in vitro analyses, we found that miR-101 targets 
the 3’UTR of the neuronal glutamate transporter SLC1A1 (also 
known as EAAC1 or EAAT3). In agreement with this result, both 
mRNA and protein levels of SLC1A1 were upregulated in the 
PFC of the FSL model. Whereas decreased levels of SLC1A1 have 
been previously reported in stress-induced offspring depression 
(Zhang et al., 2013), this is to our knowledge the first report to 
show elevated SLC1A1 levels in a depression-like state. Several 
approaches have been successfully reported to manipulate 
specific miRNA expression levels that provide possibilities for 
future in vivo examination of miR-101b function in the FSL/FRL 
model (Issler and Chen, 2015; Li et al., 2016).
In addition to having an important role in transporting glu-
tamate across neuronal membranes, SLC1A1 is also essential 
for rapidly binding released glutamate to shape synaptic trans-
mission (Tzingounis and Wadiche, 2007). SLC1A1 has also been 
found to interact with NMDA receptor subunits NR1, NR2A, and 
NR2B (Waxman et al., 2007). Interestingly, in the FSL model, 
NR2A and NR2B subunits are decreased in both the PFC and 
the hippocampus (Eriksson et al., 2012), which may suggest a 
novel coregulatory mechanism. Whereas the FSL animals dis-
play reductions in serotonin receptors (Eriksson et al., 2012), 
an independent group recently also confirmed an aberrant glu-
tamatergic transmission in this model of depression (Gomez-
Galan et al., 2013). In the latter study, the authors examined 
the hippocampal region of the FSL and found a dysfunctional 
astrocytic glutamate regulation that was accompanied by a 
downregulation of the glial glutamate transporter GLAST (also 
known as EAAT1). Obviously, our finding of increased SLC1A1 
(EAAT3) in the PFC may represent just one of many depression-
related glutamatergic and/or serotonergic genes that are being 
targeted by our validated miRNAs. This is supported by the fact 
that besides SLC1A1, one other gene that was confirmed to be 
upregulated in the PFC of the FSL was Rac1, which can be acti-
vated by serotonin through 5-HT2A receptor stimulation (Dai 
et al., 2008) and is a confirmed miR-101 target (Lin et al., 2014). 
RAC1 is a small Rho family GTPase that acts as a key regula-
tor of actin cytoskeletal dynamics. It plays an important role in 
dendritic development and spinogenesis. Dysregulation of RAC1 
has been associated with cognitive impairment, memory dis-
turbance, and neurodevelopmental disorders (Govek et al., 2005; 
Martinez and Tejada-Simon, 2011; Stankiewicz and Linseman, 
2014), which may support a role of RAC1 in the pathophysiologi-
cal process of depression. Taken together, these preclinical data 
support the shift from a solely monoamine-centered hypothesis 
in the pathophysiology of depression to one that includes the 
involvement of the glutamatergic system (Sanacora et al., 2012).
The traditional approach to identify compounds targeting 
single molecules (usually receptors or their ligands) has been a 
hinder for the development of effective psychiatric drugs, and 
an approach targeting the defective components of an entire 
biological pathway is likely more efficient. Therefore, compared 
with single-target drugs, miRNAs possess an advantage that is 
attributed to their pleiotropic nature, which allows them to indi-
vidually regulate hundreds of genes.
Supplementary Material
For supplementary material accompanying this paper, visit 
http://www.ijnp.oxfordjournals.org/
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